Hengrui Pharma: Reaches Agreement with Merck Healthcare to License Out HRS-1167 Tablets and SHR-A1904 Injection, Two Self-Owned Intellectual Property Class 1 New Drugs, for a Fee.
Hengrui Medicine Enters into Licensing Agreement with Merck Healthcare for HRS-1167 and SHR-A1904
Oct 30, 2023 16:44
CST Updated
16:44
Hengrui Pharma
Innovative and High-Quality Pharmaceutical Developer
Merck Group
Pharmaceutical R&D Developer